University of Washington
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Washington sits in the top decile of US sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count).
University of Washington: 1,048 sponsored US clinical trials, 156 recruiting.
University of Washington sponsors 1,048 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 720 completed. 104 of these trials are in Phase 3-4 (later-stage) and 320 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 13 trials.
Top-decile sponsor footprint
University of Washington ranks in the top decile of sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
720 of 816 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,048 total, page 3 of 21
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
NCT05596760
Lung Transplant READY CF 2: CARING CF Ancillary RCT
NCT06032273
Effectiveness of Frontal Plane Adaptability in a Novel Foot Prosthesis
NCT06214026
BASIS-T Efficacy Trial
NCT05989568
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
NCT05453396
Variation in Gingival Inflammatory Responses
NCT05968742
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
NCT05581589
Wakaya: Rising Up for Choctaw Youth Health
NCT05818384
A Pilot Study of The CKM JumpStart Tool
NCT05753020
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
NCT05570825
Ultrasound to Facilitate Stone Passage
NCT04796792
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
NCT05453500
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
NCT05566431
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
NCT05455697
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
NCT05632770
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
NCT06164717
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
NCT05340465
Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury
NCT05267951
Hand and Arm Motor Recovery Via Non-invasive Electrical Spinal Cord Stimulation After Stroke
NCT05591196
Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT)
NCT05970991
Spinal Stimulation and Mobility Devices
NCT05520359
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT04329065
Liver Cancer Disparities in American Indian and Alaska Native Persons
NCT05304234
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
NCT05856942
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
NCT05286931
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
NCT04797767
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT05183828
Improving HIV Diagnosis, Linkage to Care, and Prevention Services With HIV Point-of-Care Nucleic Acid Tests
NCT04880200
An Automatically Adjusting Prosthetic Socket for People With Transtibial Amputation
NCT05124652
Improving the Part C Early Intervention Service Delivery System for Children with ASD
NCT05114538
Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain
NCT04692441
Autologous Mitochondrial Transplant for Cerebral Ischemia
NCT04998357
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
NCT04489719
Lay-Delivered Behavioral Activation in Senior Centers
NCT04621877
Smart Eyewear to Automatically Detect Drug Delivery Events
NCT05184660
Transcutaneous Stimulation for Neurological Populations
NCT04467437
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
NCT04231877
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT04175431
NIH Release/Relock Socket
NCT04305782
Testosterone Levels and Cutibacterium
NCT05030220
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
NCT04472338
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
NCT04282187
Von Willebrand Factor in Pregnancy (VIP) Study
NCT04146376
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NCT04151940
Kidney Precision Medicine Project
NCT04334707
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
NCT03737955
Transcutaneous Spinal Stimulation and Exercise for Locomotion
NCT03509558
Can Conventional ECG Technology Capture Fetal Cardiac Activity?
NCT03111173
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
NCT02537769
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
NCT02025023
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 127 |
| Phase 2 | 193 |
| Phase 3 | 39 |
| Phase 4 | 65 |
What is open in the University of Washington pipeline
156 recruiting of 1,048 indexed (15% open); 720 completed (69%).
Phase mix: 104 late (III/IV) vs 320 early (I/II) (early-phase heavy).
Top condition: Depression (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Washington: open-pipeline peers nationwide
Peers matched on 1,048 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,048 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- Bristol-Myers Squibb · 1,025 trials · 7% recruiting
- University of Florida · 1,106 trials · 15% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Arizona State University · 15% recruiting · 187 trials
- Georgetown University · 15% recruiting · 227 trials
Related
What to do with this University of Washington page
1,048 registered trials is a research-attention snapshot, not an endorsement of University of Washington or any single study.
- 156 of University of Washington's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of Washington studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Washington pipeline card: 1,048 registered trials from official public datasets.Report a data error.